The results of a 24-month controlled, prospective study of relapsing multiple sclerosis patients at risk for progressive multifocal encephalopathy, who switched from prolonged use of natalizumab to teriflunomide

BACKGROUND: Natalizumab (NTZ) is a highly effective disease modifying treatment for relapsing multiple sclerosis (RMS), but it increases risk of progressive multifocal leukoencephalopathy (PML) in patients with serum anti- John Cunningham virus (JCV) antibodies. OBJECTIVE: To assess the safety and e...

Descripción completa

Detalles Bibliográficos
Autores principales: Cohan, Stanley, Gervasi-Follmar, Tiffany, Kamath, Aneesh, Kamath, Vineetha, Chen, Chiayi, Smoot, Kyle, Baraban, Elizabeth, Edwards, Keith
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8689625/
https://www.ncbi.nlm.nih.gov/pubmed/34950502
http://dx.doi.org/10.1177/20552173211066588

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8689625/
https://www.ncbi.nlm.nih.gov/pubmed/34950502
http://dx.doi.org/10.1177/20552173211066588

Ejemplares similares